Company profile: CardioMech
1.1 - Company Overview
Company description
- Provider of transcatheter devices for structural heart disease, offering an alternative to cardiac surgery for mitral valve chordal repair. Its catheter-based therapy places artificial chords to reduce or eliminate mitral regurgitation without open-heart surgery, giving surgeons new therapeutic options.
Products and services
- Mitral Valve Artificial Chord Placement Devices: Catheter-based devices that offer an alternative to cardiac surgery, enabling surgeons to place artificial chords for mitral valve, expanding options in structural heart disease
- Transcatheter Alternative to Cardiac Surgery for Mitral Valve: Mitral valve-specific system that enables artificial chord placement to address mitral regurgitation, avoiding open-heart surgery and giving surgeons access to therapeutic options
- Transcatheter Mitral Valve Chordal Repair Technology: Therapy that reduces or eliminates mitral regurgitation by placing artificial chords in the heart without open-heart surgery.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to CardioMech
ReCor Medical
HQ: United States
Website
- Description: Provider of a therapeutic non-focused ultrasound system for renal denervation in resistant hypertension. Offers the PARADISE Percutaneous Renal Denervation System with a 6 French catheter and cylindrical transducer emitting circumferential ultrasound, the SonoWave 360 Transducer, HydroCooling System, clinical trials proving effectiveness, and reimbursement resources for coding and coverage.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ReCor Medical company profile →
Centese
HQ: United States
Website
- Description: Provider of cardiothoracic post-operative medical equipment for surgical care and patient monitoring, including Thoraguard, a compact all-in-one system with digital monitor, suction control, canister, and chest tubes. Features automated chest tube clog clearance, precise digital air leak rate monitoring, hourly drainage volume trends, and self-monitoring alerts for cardiac and thoracic surgery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Centese company profile →
LipoScience
HQ: United States
Website
- Description: Provider of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. Its first proprietary diagnostic test, the NMR LipoProfile® test, measures the number of low density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LipoScience company profile →
GB Sciences
HQ: United States
Website
- Description: Provider of research and biotechnical development focused on plant-based therapeutics, including the PhAROS AI drug discovery platform to identify and predict active ingredients; therapies for Parkinson’s disease (animal proof-of-concept, US patent); COVID-related cytokine release syndrome therapies (positive proof-of-concept); and oral nanoparticle pain therapeutics (US patent, ongoing animal studies).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GB Sciences company profile →
Prevencio
HQ: United States
Website
- Description: Provider of multi-proteomic cardiovascular blood tests: HART CVE uses a machine learning algorithm to predict 1-year risk of heart attack, stroke, or cardiac death; HART CADhs detects obstructive coronary artery disease; HART PAD diagnoses obstructive peripheral artery disease; HART AS diagnoses and monitors aortic valve stenosis (98% exclusion accuracy); HART Amputation Risk assesses amputation risk (87% accuracy).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prevencio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for CardioMech
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to CardioMech
2.2 - Growth funds investing in similar companies to CardioMech
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for CardioMech
4.2 - Public trading comparable groups for CardioMech
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →